As the malaria parasite continues to evolve, science must keep pace

Ashley Birkett, director of MVI, discusses the increasing threat of drug-resistant malaria parasites and the importance of developing new tools to eliminate and eventually eradicate malaria altogether.

Read more »

mosquitoes feeding

Photo credit: F. Beilhe


World Immunization Week banner

Partnering with us

PuzzleWe are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.

Our portfolio

MVI portfolioWe maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.

View the portfolio »Subscription button

What we do and how we do it

MVI overview imageWe identify potentially promising malaria vaccine approaches and systematically move them through the development process. At the same time, we work to catalyze access to a successful malaria vaccine in the countries that need it most.

Read more »



News and announcementsWalking together: Steve Davis reflects on 15 years of Gavi partnership

This week on Gavi’s blog, Steve Davis, president and CEO of PATH, provided insight on what it takes to develop and strengthen a global community of scientists, policymakers, advocates, regulators, medical workers, and caregivers to continue our good work.


Malaria vaccine gets a shot in the arm

MVI announces $156 million grant from Bill & Melinda Gates Foundation to support essential vaccine role in strategy to eradicate malaria.


Japan's Global Health Innovative Technology Fund announces award to MVI

MVI welcomes announcement by Japan’s Global Health Innovative Technology Fund of a grant to MVI and its partner Ehime University to fast-track the development of a novel malaria vaccine candidate. The new vaccine approach is targeted at blocking malaria parasite transmission between humans and mosquitoes.

Events and Conferences

Global Conference on Vaccines
April 13–15, 2015